French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) on Thursday reported positive topline Phase III results from its BEOND migraine programme, with Dysport (abobotulinumtoxinA) meeting the primary endpoint in both episodic and chronic migraine trials by reducing monthly migraine days versus placebo.

The E-BEOND trial marked the first Phase III study in which a botulinum toxin demonstrated statistically significant efficacy in episodic migraine, while the combined BEOND programme is the first to show efficacy of a botulinum toxin in preventing both episodic and chronic migraine. Dysport was well tolerated across both studies, with a safety profile consistent with its established use and no new or unexpected safety signals.

Ipsen said the results position Dysport as a potential first-in-class treatment for a broad migraine population. The company noted that episodic migraine represents a substantially larger patient population than chronic migraine, highlighting a significant unmet medical need.